Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics of vortioxetine and its
metabolites Lu AA34443 and Lu AA39835 following a single oral dose administration of
vortioxetine 5 mg in participants with severe hepatic impairment compared to healthy
participants.